Evidence map›Paper›PMID 28740126›Full record

ArticleNature communications2017

Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.

Manav Korpal, Xiaoling Puyang, Zhenhua Jeremy Wu, Roland Seiler, Craig Furman, Htoo Zarni Oo, Michael Seiler, Sean Irwin, Vanitha Subramanian, Jaya Julie Joshi and 29 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 143 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Dual function of activated PPARγ by ligands on tumor growth and immunotherapy.Medical oncology (Northwood, London, England) · 2024
    Review
  19. Review
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

39 authors at 3 institutions in 3 countries.

Manav KorpalH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA. Manav.korpal@outlook.com.
Xiaoling PuyangH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Zhenhua Jeremy WuH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Roland SeilerDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.
Craig FurmanH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Htoo Zarni OoDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.
Michael SeilerH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Sean IrwinH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Vanitha SubramanianH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Jaya Julie JoshiH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Chris K WangDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.
Victoria RimkunasH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Davide TortoraDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.
Hua YangEisai Inc., 4 Corporate Drive, Andover, MA, 01810, USA.
Namita KumarEisai Inc., 4 Corporate Drive, Andover, MA, 01810, USA.
Galina KuznetsovEisai Inc., 4 Corporate Drive, Andover, MA, 01810, USA.
Mark MatijevicEisai Inc., 4 Corporate Drive, Andover, MA, 01810, USA.
Jesse ChowEisai Inc., 4 Corporate Drive, Andover, MA, 01810, USA.
Pavan KumarH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Jian ZouH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Jacob FealaH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Laura CorsonH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Ryan HenryH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Anand SelvarajH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Allison DavisH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Kristjan BloudoffH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
James DouglasDepartment of Urology, University Hospital of Southampton, Hampshire, SO16 6YD, UK.
Bernhard KissDepartment of Urology, University of Bern, Bern, CH-3010, Switzerland.
Morgan RobertsDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.
Ladan FazliDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.
Peter C BlackDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.
Peter FekkesH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Peter G SmithH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Markus WarmuthH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Lihua YuH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Ming-Hong HaoH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Nicholas LarsenH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA.
Mads DaugaardDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, V5Z 1M9.
Ping ZhuH3 Biomedicine Inc., 300 Technology Square, Cambridge, MA, 02139, USA. Ping_Zhu@h3biomedicine.com.
University of British Columbia · CAEisai (United States) · USUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Muscle-invasive bladder cancer (MIBC) is an aggressive disease with limited therapeutic options. Although immunotherapies are approved for MIBC, the majority of patients fail to respond, suggesting existence of complementary immune evasion mechanisms. Here, we report that the PPARγ/RXRα pathway constitutes a tumor-intrinsic mechanism underlying immune evasion in MIBC. Recurrent mutations in RXRα at serine 427 (S427F/Y), through conformational activation of the PPARγ/RXRα heterodimer, and focal amplification/overexpression of PPARγ converge to modulate PPARγ/RXRα-dependent transcription programs. Immune cell-infiltration is controlled by activated PPARγ/RXRα that inhibits expression/secretion of inflammatory cytokines. Clinical data sets and an in vivo tumor model indicate that PPARγ

Indexed as

Monitoring, ImmunologicAnimalsCD8-Positive T-LymphocytesCell Line, TumorCytokinesGene Expression ProfilingHCT116 CellsHumansImmune EvasionImmunoblottingImmunotherapyInflammation MediatorsMiceMicroscopy, FluorescenceMutationNeoplasm InvasivenessCytokinesInflammation MediatorsPPAR gammaRetinoid X Receptor alpha

Identifiers

PMID28740126
PMCPMC5524640
OpenAlexW2734446741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.